SOUTH SAN FRANCISCO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a clinical stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today announced the company will give two data presentations at ACR Convergence 2024, the annual meeting of the American College of Rheumatology (ACR), being held November 14–19, 2024, in Washington, D.C. Data to be presented at ACR show that treatment with ESK-001, a highly selective allosteric oral tyrosine kinase 2 (TYK2) inhibitor, suppresses both a novel disease biomarker as well as Type 1 inte

– Presented data at EADV supporting potential of ESK-001 as differentiated oral treatment in immune-mediated diseases through maximal TYK2 inhibition – – Continued to advance three clinical programs, including global Phase 3 ONWARD clinical trials for ESK-001 in moderate-to-severe plaque psoriasis, Phase 2b clinical trial for ESK-001 in systemic lupus erythematosus (SLE) and Phase 1 clinical study for A-005 being developed for neuroinflammatory and neurodegenerative diseases – SOUTH SAN FRANCISCO, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcome

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today announced that Martin Babler, President and Chief Executive Officer of Alumis, will participate in a fireside chat at Guggenheim's Inaugural Healthcare Innovation Conference on Tuesday, November 12, 2024 at 2:00 pm ET in Boston, MA. A live webcast will be available on the Alumis website in the "Investors" section under the "Events" page. A replay of the conference webcast will be archived on t

28-week data show ESK-001 was generally well tolerated and most patients treated with the top dose of 40 mg twice daily achieved PASI 75Three additional data presentations further support ESK-001's potential to offer a highly differentiated and best-in-class treatment profile for people with moderate-to-severe plaque psoriasisFull 52-week Phase 2 OLE dataset expected 1H 2025; Phase 3 clinical program ongoing SOUTH SAN FRANCISCO, Calif., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a clinical stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today announced that company management will participate in the following investor conferences in September: Morgan Stanley 22nd Annual Global Healthcare ConferenceThursday, September 5, 2024, 8:30 am ETNew York, NY Format: fireside chat and one-on-one investor meetings 2024 Wells Fargo Healthcare ConferenceFriday, September 6, 2024Boston, MAFormat: one-on-one investor meetings only Baird 2

– Initiated patient dosing in ESK-001 Phase 3 ONWARD clinical program in moderate-to-severe plaque psoriasis – – Initiated Phase 1 clinical trial for A-005 in healthy participants – – Completed IPO and private placement raising gross proceeds of $250M – SOUTH SAN FRANCISCO, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today reported financial results for the second quarter ended June 30, 2024, and provided a summary of recent corporate achievements and upcoming

– Co-primary endpoint of PASI 75 and sPGA 0/1 score at 24 weeks to serve as basis for U.S. regulatory submission – – Pivotal Phase 3 program supported by positive Phase 2 STRIDE clinical data as well as ongoing open-label extension (OLE) study – – Topline data anticipated in 2026 – SOUTH SAN FRANCISCO, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today announced that patient dosing has commenced in the ONWARD Phase 3 clinical program. This Phase 3 program consis

4/A - ALUMIS INC. (0001847367) (Issuer)

4 - ALUMIS INC. (0001847367) (Issuer)

4 - ALUMIS INC. (0001847367) (Issuer)

4 - ALUMIS INC. (0001847367) (Issuer)

4 - ALUMIS INC. (0001847367) (Issuer)

4 - ALUMIS INC. (0001847367) (Issuer)

4 - ALUMIS INC. (0001847367) (Issuer)

4 - ALUMIS INC. (0001847367) (Issuer)

4 - ALUMIS INC. (0001847367) (Issuer)

4 - ALUMIS INC. (0001847367) (Issuer)

4/A - ALUMIS INC. (0001847367) (Issuer)

4 - ALUMIS INC. (0001847367) (Issuer)

4 - ALUMIS INC. (0001847367) (Issuer)

4 - ALUMIS INC. (0001847367) (Issuer)

SC 13D - ALUMIS INC. (0001847367) (Subject)

SC 13G - ALUMIS INC. (0001847367) (Subject)

SC 13D - ALUMIS INC. (0001847367) (Subject)

SC 13D - ALUMIS INC. (0001847367) (Subject)

Robert W. Baird initiated coverage of Alumis with a rating of Outperform and set a new price target of $25.00

H.C. Wainwright initiated coverage of Alumis with a rating of Buy and set a new price target of $30.00

Cantor Fitzgerald initiated coverage of Alumis with a rating of Overweight

Leerink Partners initiated coverage of Alumis with a rating of Outperform and set a new price target of $29.00

Guggenheim initiated coverage of Alumis with a rating of Buy and set a new price target of $32.00

Morgan Stanley initiated coverage of Alumis with a rating of Overweight and set a new price target of $36.00

Guggenheim Partners initiated coverage on Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing oral therapies for immune-mediated diseases. The investment thesis centers around a positive view of its lead asset ESK-001, a next-gen TYK2 inhibitor currently in development for plaque psoriasis and systemic lupus erythematosus (SLE). The company’s management expects to initiate a Phase 3 trial for plaque psoriasis in the second half of 2024, and data from the SLE study are expected in 2026. The analyst writes that favorable safety (with no risk of JAK class black box warning) and potential BIC efficacy make ESK-001 a potentially competitive alternative to ava

CORRECTION: Cantor Fitzgerald analyst Eric Schmidt initiates coverage on Alumis (NASDAQ:ALMS) with a Overweight rating.

Guggenheim analyst Yatin Suneja initiates coverage on Alumis (NASDAQ:ALMS) with a Buy rating and announces Price Target of $32.

Cantor Fitzgerald analyst Eric Schmidt initiates coverage on Alumis (NASDAQ:ALMS) with a Overweight rating and announces Price Target of $13.

Leerink Partners analyst Thomas Smith initiates coverage on Alumis (NASDAQ:ALMS) with a Outperform rating and announces Price Target of $29.

Morgan Stanley analyst Terence Flynn initiates coverage on Alumis (NASDAQ:ALMS) with a Overweight rating and announces Price Target of $36.